Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Monsanto    MON

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Monsanto : Large U.S. farm study finds no cancer link to Monsanto weedkiller

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 04:42pm CET
Farmer Edward Ford demonstrates granules of the weedkiller glyphosate on his arable farm in Brentwood

- A large long-term study on the use of the big-selling weedkiller glyphosate by agricultural workers in the United States has found no firm link between exposure to the pesticide and cancer, scientists said on Thursday.

Published in the Journal of the National Cancer Institute (JNCI), the study found there was no association between glyphosate, the main ingredient in Monsanto's popular herbicide RoundUp, "and any solid tumours or lymphoid malignancies overall, including non-Hogkin Lymphoma (NHL) and its subtypes".

It said there was "some evidence of increased risk of acute myeloid leukaemia (AML) among the highest exposed group", but added this association was "not statistically significant".

The findings are likely to impact legal proceedings in the United States against Monsanto, in which more than 180 plaintiffs are claiming exposure to RoundUp gave them cancer - allegations that Monsanto denies.

The findings may also influence a crucial decision due by the end of the year on whether glyphosate should be re-licensed for sale across the European Union.

EU countries had been due to vote on the issue on Thursday, but again failed to agree to a proposal for a five-year extension.

The EU decision has been delayed for more than a year after the World Health Organization's International Agency for Research on Cancer (IARC) reviewed glyphosate in 2015 and concluded it was "probably carcinogenic" to humans. Other bodies, such as the European Food Safety Authority, have concluded glyphosate is safe to use.

The research is part of a large and important project known as the Agricultural Health Study (AHS), which has been tracking the health of tens of thousands of agricultural workers, farmers and their families in Iowa and North Carolina.

Since the early 1990s, it has gathered and analysed detailed information on the health of participants and their families, and their use of pesticides, including glyphosate.

David Spiegelhalter, a professor of the Public Understanding of Risk at Britain's Cambridge University who has no link to the research, said Thursday's findings were from a "large and careful study" and showed "no significant relationship between glyphosate use and any cancer".

He added that the possible association with AML "is no more than one would expect by chance" and was not a concern.

Reuters reported in June how an influential scientist was aware of new AHS data while he was chairing a panel of experts reviewing evidence on glyphosate for the International Agency for Research on Cancer (IARC) in early 2015.

But since it had not at that time been published, he did not tell the expert panel about it and IARC's review did not take it into account.

The publication of the study on Thursday comes more than four years since drafts based on the AHS data on glyphosate and other pesticides were circulating in February and March 2013.

In a summary of the results, the researchers, led by Laura Beane Freeman, principal investigator of the AHS at the U.S. National Cancer Institute, said that among 54,251 (pesticide) applicators studied, 44,932, or 82.9 percent, used glyphosate.

"Glyphosate was not statistically significantly associated with cancer at any site," the summary said.

Scott Partridge, Monsanto's vice president of strategy, said the study results clearly showed the weedkiller was safe.

"This is the largest study of agricultural workers in history, over the longest period of time," he told Reuters. "It is the gold standard,... and it definitively demonstrates in a real-world environment that glyphosate doesn't cause cancer."

(Reporting by Kate Kelland, Editing by Gareth Jones)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MONSANTO
01/19 MONSANTO : Patent Issued for Soybean Variety XR36Z15X (USPTO 9861054)
01/19 MONSANTO : Patent Issued for Soybean Variety XR56J15X (USPTO 9861056)
01/19 MONSANTO : Patent Issued for Soybean Variety XR36AC15X (USPTO 9861053)
01/19 MONSANTO : Patent Issued for Plants and Seeds of Hybrid Corn Variety CH603226 (U..
01/19 MONSANTO : Patent Issued for Soybean Variety XR39U15X (USPTO 9861055)
01/17 MONSANTO : Free Research Report as Monsanto’s Revenue Grew 0.3%, EPS Soared 442...
01/11 MONSANTO : Patent Issued for Soybean Variety 01058360 (USPTO 9854772)
01/11 MONSANTO : Patent Issued for Cotton Variety 15R510B2XF (USPTO 9854761)
01/11 MONSANTO : Patent Issued for Recombinant DNA Constructs Employing Site-Specific ..
01/11 MONSANTO : Patent Issued for Soybean Variety 01058444 (USPTO 9854773)
More news
News from SeekingAlpha
01/23 7 Agricultural Stocks For Timely Diversification (Video)
01/22 REUTERS : Brazil says Monsanto's Intacta patent should be voided
01/22 With Glencore And ADM As Suitors, BG Could Remain Twice Shy
01/19 Arkansas to restrict weedkiller in blow to Monsanto, BASF
01/19 Monsanto/Bayer nearing DOJ green light - Capital Forum
Financials ($)
Sales 2018 15 241 M
EBIT 2018 3 717 M
Net income 2018 2 457 M
Debt 2018 5 362 M
Yield 2018 1,82%
P/E ratio 2018 21,98
P/E ratio 2019 20,49
EV / Sales 2018 3,85x
EV / Sales 2019 3,63x
Capitalization 53 260 M
Duration : Period :
Monsanto Technical Analysis Chart | MON | US61166W1018 | 4-Traders
Technical analysis trends MONSANTO
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 126 $
Spread / Average Target 3,9%
EPS Revisions
Hugh M. Grant Chairman & Chief Executive Officer
Brett D. Begemann President & Chief Operating Officer
Pierre C. Courduroux Chief Financial Officer & Senior Vice President
Robert T. Fraley Chief Technology Officer & Executive VP
Robert J. Stevens Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MONSANTO3.32%53 260
UPL LTD6.89%6 480
OCI NV0.19%5 423